Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01245101 · ClinicalTrials.gov registry record · Phase 4
Addition of Raltegravir to Established Antiretroviral Suppressive Therapy
A Phase 4 study, sponsored by University of Miami.
- Terminated
- Registry status
- Phase 4
- Development phase
- 15
- Enrollment target
NCT01245101 is a Phase 4 study that was terminated before completion, run by University of Miami. The registered enrollment target is 15 participants.
The verdict
NCT01245101, a Phase 4 study, was terminated before completion, sponsored by University of Miami.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 15 participants
- Enrollment target
Study Summary
This study will examine whether intensification with raltegravir of a suppressive antiretroviral regimen in HIV infected patients with poor immune restoration has a beneficial effect on cryptic viral replication and the immune system. Specifically, the investigators will examine the effect that raltegravir intensification of ART has on episomal cDNA frequencies, immune activation, CD4+ cell counts and apoptosis, and markers of microbial translocation.
Interventions
- DRUG Raltegravir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2010-11 |
| Est. Completion | 2013-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01245101
The ClinicalTrials.gov registry entry for NCT01245101 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Miami, which has 721 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Raltegravir is the first listed.
NCT01245101 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01245101 about?
NCT01245101 is a clinical study titled "Addition of Raltegravir to Established Antiretroviral Suppressive Therapy". This study will examine whether intensification with raltegravir of a suppressive antiretroviral regimen in HIV infected patients with poor immune restoration has a beneficial effect on cryptic viral replication and the immune system. Specifically, the investigators will examine the effect that ralt...
What is the current status of trial NCT01245101?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 15 participants. The study started on 2010-11. Estimated completion is 2013-05.
What interventions are being tested in trial NCT01245101?
The interventions under investigation include: Raltegravir (DRUG).
Who is sponsoring clinical trial NCT01245101?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.